Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyanidin is a natural organic compound classified as an anthocyanidin, a type of plant pigment responsible for the red, blue, and purple colors in various fruits and vegetables such as berries and red grapes. In oncological research, cyanidin has demonstrated potential antimetastatic and chemopreventive properties. Specifically, it has been shown to inhibit the Transforming Growth Factor-beta (TGF-beta)-induced epithelial-mesenchymal transition (EMT) in glioblastoma cells. This pharmacological effect is mediated through the down-regulation of mesenchymal markers like fibronectin and snail, as well as the inhibition of Smad2, ERK, and JNK signaling pathways. While primarily recognized as a dietary constituent and nutraceutical, its ability to modulate cellular migration and invasiveness makes it a subject of interest in cancer prevention and treatment strategies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyanidin.